The Paris-based company plans to use the nucleic acid modification technology to synthesize qPCR probes for use in diagnostics, among other biomolecules.
The firm reported $28.2 million in revenues for the three months ended Dec. 31, 2020, beating consensus Wall Street estimates on the top and bottom lines.
The investment bank said that while Twist's biopharma and DNA-based data storage businesses offer upside, the timelines for generating revenues are unclear.
